galeterone

DRUG4 trials

Sponsors

LTN PHARMACEUTICALS, INC., University of Maryland, Baltimore

Conditions

Advanced Pancreatic CancerHealthyProstate Cancer

Phase 1

Single-Dose Study to Assess the Absorption, Metabolism, Excretion, and Mass Balance of Radiolabeled Galeterone

CompletedNCT02729376

LTN PHARMACEUTICALS, INC.Healthy

Start: 2016-03-31End: 2016-04-30Updated: 2020-09-04

Phase 2

A 2 Part, Phase 2 Trial of Galeterone in the Treatment of Castration Resistant Prostate Cancer

TerminatedNCT01709734

LTN PHARMACEUTICALS, INC.Prostate Cancer

Start: 2012-12-31End: 2016-09-30Updated: 2023-03-15

1911GCCC: Galeterone With Gemcitabine for Patients With Metastatic Pancreatic Adenocarcinoma

Active, not recruitingNCT04098081

University of Maryland, BaltimoreAdvanced Pancreatic Cancer

Start: 2019-12-12End: 2026-12-31Updated: 2026-07-01

Phase 3

A Study of Galeterone Compared to Enzalutamide In Men Expressing Androgen Receptor Splice Variant-7 mRNA (AR-V7) Metastatic CRPC

TerminatedNCT02438007

LTN PHARMACEUTICALS, INC.Prostate Cancer

Start: 2015-06-30End: 2016-11-30Updated: 2023-03-15

Related Papers

Galeterone and gemcitabine in advanced pancreatic ductal adenocarcinoma.

Journal of Clinical Oncology2026-05-28

Galeterone monotherapy in advanced pancreatic ductal adenocarcinoma: Results from a phase two trial.

Journal of Clinical Oncology2025-01-27

Clinical factors associated with AR-V7 detection in ARMOR3-SV, a randomized trial of galeterone (Gal) vs enzalutamide (Enz) in men with AR-V7+ metastatic castration-resistant prostate cancer (mCRPC).

Journal of Clinical Oncology2017-05-2030 citations

An imaging agent to detect androgen receptor and its active splice variants in prostate cancer

JCI Insight2016-07-2022 citations

Randomized, open-label, multicenter, controlled study of galeterone vs enzalutamide in men with metastatic castration-resistant prostate cancer (mCRPC) expressing AR-V7 splice variant (ARMOR3-SV).

Journal of Clinical Oncology2016-05-202 citations

Galeterone in treatment-naïve patients with castration-resistant prostate cancer with C-terminal androgen receptor loss: Results from ARMOR2.

Journal of Clinical Oncology2016-05-201 citations

Implementing a CTC-based clinical trial assay for selecting AR-V7+ patients for enrollment in a pivotal phase 3 study (ARMOR3-SV).

Journal of Clinical Oncology2016-01-10

Activity of sequential therapies (txs) in patients (pts) with castration resistant prostate cancer (CRPC) previously treated with galeterone.

Journal of Clinical Oncology2015-05-201 citations

Galeterone in men with CRPC: Results in four distinct patient populations from the ARMOR2 study.

Journal of Clinical Oncology2014-05-2010 citations